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Recent advances in statins and the kidney. tent of glomerular injury in 5/6 nephrectomy Sprague-
Background. Experimental and clinical studies have sug- Dawley rats [1], obese Zucker rats [2], Dahl-sensitive
gested a correlation between the progression of renal disease
rats [3], guinea pigs (abstract; Gro¨ne et al, J Am Socand dyslipidemia. Indeed, apolipoprotein B-containing lipo-
Nephrol 3:739, 1992), and the puromycin aminonucleo-proteins have been demonstrated to be an independent risk
factor for the progression of renal disease in humans. Interven- side model of the nephrotic syndrome [4]. Lovastatin also
tional strategies in experimental models of renal disease have retarded the development of polycystic kidney disease in
clearly demonstrated a beneficial effect on renal structure and
the Han:SPRD rats [5], ischemic renal failure in high-function in a variety of models of renal disease. Investigations
cholesterol–loaded rats [6], and hypertension in sponta-into the mechanisms whereby reduction of lipids by lipid-low-
ering agents benefits renal disease have suggested that the neously hypertensive rats [7]. Simvastatin suppressed the
3-hydroxy-3-methylglutaryl coenzyme reductase inhibitors, the cell proliferation in rats with anti–Thy-1.1 nephritis [8].so-called statin class of lipid-lowering agents, may have addi-
Interestingly, some of the beneficial effects of statinstional effects on the biology of inflammation that are germane
to the progression of renal disease. can be seen independent of the cholesterol reduction
Methods. Both in vivo and in vitro studies that investigated (abstract; Kauffman et al, FASEB J 319:8, 1994) [4, 9].
secondary mechanisms of statin effects are reviewed. In addi-
These beneficial effects of statins on these in vivo animaltion, new studies that investigated the effects on novel cellular
models have been investigated using in vitro studies. Inmechanisms are presented.
Results. Lipid-lowering agents appear to have biologically this regard, the effects of statins on the interaction of
important effects in modulating a variety of intracellular signal- inflammatory cytokines, cell proliferation, and intracel-
ing systems involved in cell proliferation, inflammatory re-
lular signaling pathways have recently been reported.sponses that involve macrophage adhesion, recruitment, and
maturation. In addition, the effects on fibrogenesis have been
recently defined. These latter effects may influence not only the
development of glomerulosclerosis, but also interstitial fibrosis. STATINS AND INFLAMMATORY CHEMOKINES
These potentially major effects of lipid-lowering agents appear
Macrophages participate in the uptake and metabo-to be related to the effects on intracellular synthesis of nonste-
rol isoprenoids, which are involved in prenylation of critical lism of lipids in glomeruli, which may play a critical role
small molecular weight proteins involved in cell signal trans- in the pathogenesis of lipid-induced glomerulosclerosis
duction.
[10–12]. The mechanisms whereby monocytes are re-Conclusions. In addition to the beneficial effects of the re-
cruited to glomeruli are poorly understood; however,duction in serum lipids, statins and other lipid-lowering agents
may influence important intracellular pathways that are in- mesangial cells stimulated by lipids [13] or inflammatory
volved in the inflammatory and fibrogenic responses, which cytokines have been shown to produce important mono-
are common components of many forms of progressive renal
cyte chemokines such as monocyte chemoattractantinjury.
protein-1 (MCP-1) and macrophage-colony stimulating
factor (M-CSF) [14, 15]. We have reported that lovastatin
can reduce in vitro mesangial cell expression and the pro-Experimental evidence suggests that lipids are impor-
duction of MCP-1 [16, 17] and M-CSF, as well as vasculartant modulators of progressive renal disease. In recent
years, the inhibitors of 3-hydroxy-3-methylglutaryl coen- cell adhesion molecule-1 (VCAM) and intracellular adhe-
zyme A (HMG-CoA) reductase, so called “statins,” have sion molecule-1 (ICAM-1), which are integral adhesion
demonstrated beneficial effects in different models of molecules [18]. Moreover, lovastatin inhibited the activa-
progressive renal failure. Lovastatin ameliorated the ex- tion of transcription factor nuclear factor-kB (NF-kB),
which plays a major role in the gene expression involved
in mesangial cell inflammatory responses [19], suggestingKey words: fibrinogen, dyslipidemia, apolipoprotein, lipid-lowering
agents. that statins have modulating effects on the intracellular
signaling pathways activated by inflammation. 1999 by the International Society of Nephrology
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STATINS AND CELL PROLIFERATION cycle regulation has received considerable attention. Lo-
vastatin induced p27kip1, a cyclin-dependent kinase in-We and others have reported that mesangial cells pro-
hibitor, resulting in a cell-cycle arrest at G1 phase [38,liferate in response to various growth factors such as
39]. These effects of statins on nuclear events may beplatelet-derived growth factor (PDGF), insulin, and in-
explained by the observation that pravastatin inhibitedsulin-like growth factor-1, as well as lipoproteins such
geranylgeranylation of p21RhoA and p21RhoB, twoas low-density lipoprotein (LDL), intermediate density
small GTPase(s). Isoprenylation of these factors is essen-lipoprotein (IDL), and very low-density lipoprotein
tial for p27Kip1 degradation and subsequent cell-cycle(VLDL) [20–22]. In vitro experiments have shown that
progression from the G1 to S phase [40]. In our study,statins inhibit proliferation of cultured mesangial cells
lovastatin reduced DNA synthesis by inducing p27Kip1[23, 24], renal epithelial tubular cells [25], and vascular
and suppressing cyclin D1 and E expression in culturedsmooth muscle cells [26–28]. Although statins inhibit
rat vascular smooth muscle cells [41].intracellular cholesterol synthesis, they also inhibit the
Additional cellular effects of statins have been re-formation of intermediate metabolites of the mevalonate
ported in recent studies. For example, simvastatin haspathway [23], particularly the nonsterol isoprenoids,
been shown to improve vascular hemodynamic re-which appear to be essential in cell replication.
sponses, suggesting a direct or indirect effect on endothe-
lial-derived nitric oxide [42]. Atorvastatin and simva-
INVOLVEMENT OF STATINS IN THE statin were able to prevent the reduction in mRNA
SIGNALING PATHWAYS expression and protein levels of endothelial cell nitric
Mevalonate was reported to be an important product oxide synthase after exposure to oxidized LDL [43]. Pra-
of HMG-CoA reductase for the progression of a cell vastatin [44] and lovastatin [45] have also been reported
cycle [29–31]. Recently, however, the important roles of to improve vasomotor tone and endothelial function in
the mevalonate metabolites such as farnesyl pyrophos- patients with coronary artery disease in association with
phate (FPP) and geranylgeranyl pyrophosphate (GGPP) cholesterol reduction. The inhibitory effects of lovastatin
have been demonstrated to be indispensable anchors of and fluvastatin on platelet activation have been shown
small G proteins, such as p21ras, that allow it to bind to to reduce platelet aggregation via altered platelet lipid
the cell membrane [32–34]. Binding of certain growth composition [46].
factors to its receptor induces p21ras activation in combi- Thus, both in vitro and in vivo studies have demon-
nation with Grb2-Sos-Shc binding to the receptor and strated that statins may have important effects on the
p21ras. The signal is transmitted to the nucleus through pathophysiology of progressive renal disease by modi-
a pathway that consists of Raf, MAPK-ERK kinase, and fying monocyte infiltration, mesangial cell proliferation,
the mitogen-activated protein (MAP) kinase cascade. In and mesangial matrix expansion, as well as tubulointer-
the nucleus, the transcription factors such as activated stitial inflammation and fibrosis. These effects appear to
protein-1 (AP-1), NF-kB, NF-interleukin-6 (NF-IL-6), be related, at least in part, to inhibition of small
and Egr-1 are induced, as well as early response genes, G-protein isoprenylation involved in early gene prod-
and subsequent cell proliferation or differentiation oc- ucts, transcription factors, and modulation of the cell-
curs. Reduction of FPP and GGPP by statins may effec- cycle regulatory proteins. Although these data need fur-
tively block the p21ras-mediated mitogenic signaling ther study in humans, statins may be an important and
event [19, 35]. Lovastatin suppressed the expression of beneficial therapeutic strategy for progressive renal dis-
c-fos and c-jun in conjunction with a reduction in mem- eases.
brane-bound p21ras. In addition, it has been shown in
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tubulointerstitial inflammation in models of progressive
renal disease. Lovastatin has recently been shown to
APPENDIXinhibit isoprenylation of p21RhoA, a small G protein,
and thereby induce apoptosis by inhibiting mitotic and Abbreviations used in the paper are: AP-1, activator protein-1; Egr-
1, early growth response factor-1; ERK, extracellular signal-regulatedpostmitotic signals in cultured mesangial cells [36]. Simi-
protein; Grb2, growth factor receptor-bound protein 2; HMG-CoA,larly, atorvastatin decreased isoprenylation of p21RhoB,
3-hydroxy-methylglutaryl coenzyme A; ICAM-1, intracellular adhe-
a small G protein, and induced apoptosis in vascular sion molecule-1; LDL, low density lipoprotein; MAPK, mitogen acti-
vated protein kinase; MCP-1, monocyte chemoattractant protein-1;smooth muscle cells in culture [37]. Thus, statins appear
M-CSF, macrophage-colony stimulating factor; MEK, MAPK-ERKto regulate cellular signaling pathways involved in prolif-
kinase; NF-kB, nuclear factor-kB; PDGF, platelet-derived growth fac-
eration and apoptosis. tor; Shc, SH2 containing protein; Sos, son of sevenless; VCAM-1,
vascular cell adhesion molecule-1.In recent years, the involvement of statins in the cell-
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